Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients

Autor(es)

Aquino, Adriano ^[1] ; Alexandrino, Guilherme L. ^[2] ; Guest, Paul C. ^[1] ; Augusto, Fabio ^[2] ; Gomes, Alexandre F. ^[3] ; Murgu, Michael ^[3] ; Steiner, Johann ^{[4, 5]} ; Martins-de-Souza, Daniel ^{[6, 7, 1]}

Afiliação do(s) autor(es)

^[1] Univ Estadual Campinas, Inst Biol, Dept Biochem & Tissue Biol, Lab Neuroprote, Campinas, SP - Brazil

^[2] Univ Estadual Campinas, Inst Chem, Gas Chromatog Lab, Campinas, SP - Brazil

^[3] Waters Corp, Mass Spectrometry Applicat & Dev Lab, Sao Paulo - Brazil

^[4] Ctr Behav Brain Sci, Magdeburg - Germany

^[5] Univ Magdeburg, Dept Psychiat & Psychotherapy, Magdeburg - Germany

^[6] Univ Estadual Campinas, Neurobiol Ctr, Campinas, SP - Brazil

^[7] Conselho Nacl Desenvolvimento Cient & Tecnol, Inst Nacl Biomarcadores Neuropsiquiatria INBION, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: FRONTIERS IN PSYCHIATRY; v. 9, MAY 25 2018.
• Citações Web of Science: 2

Resumo

This is the first study to identify lipidomic markers in plasma associated with response of acutely ill schizophrenia patients in response to specific antipsychotic treatments. The study population included 54 schizophrenia patients treated with antipsychotics for 6 weeks. Treatment led to significant improvement in positive and negative symptoms for 34 patients with little or no improvement for 20 patients. In addition, 37 patients showed an increase in body mass index after the 6 week treatment period, consistent with effects on metabolism and the association of such effects with symptom improvement. Profiling of plasma samples taken prior to therapy using liquid chromatography tandem mass spectrometry (LC-MS/MS) resulted in identification of 38, 10, and 52 compounds associated with the olanzapine, risperidone, and quetiapine treatment groups, which could be used to distinguish responders from non-responders. Limitations include the retroactive active nature of the study and the small sample size. Further investigations with larger sample sets could lead to the development of a molecular test that could be used to help psychiatrists determine the best treatment options for each patient. (AU)

• Processo FAPESP: 17/25588-1 - Da compreensão básica a biomarcadores clínicos para a esquizofrenia: um estudo multidisciplinar centrado na neuroproteômica
• Beneficiário: Daniel Martins-de-Souza
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 15/08201-0 - Petroleômica: uma abordagem utilizando a cromatografia bidimensional "abrangente" acoplada à espectrometria de massas e a quimiometria
• Beneficiário: Guilherme Lionello Alexandrino
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 15/09159-8 - Desenvolvimento de plataformas para estudos de lipidômica e seu emprego na avaliação da resposta a antipsicóticos em pacientes com esquizofrenia
• Beneficiário: Adriano Aquino
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 13/08711-3 - Desenvolvimento de um teste preditivo para medicação bem sucedida e compreensão das bases moleculares da esquizofrenia através da proteômica
• Beneficiário: Daniel Martins-de-Souza
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores
• Processo FAPESP: 14/10068-4 - EMU concedido no processo 13/08711-3: espectrômetro de massas Waters SYNAPT G2-Si HDMs + nanoACQUITY UPLC
• Beneficiário: Daniel Martins-de-Souza
• Modalidade de apoio: Auxílio à Pesquisa - Programa Equipamentos Multiusuários